Measurement of total antioxidant response in colorectal cancer using a novel automated method

Özgönül, Abdullah; Aksoy, Nurten; Dilmeç, Fuat; Uzunköy, Ali; Aksoy, Şahin
August 2009
Turkish Journal of Medical Sciences;2009, Vol. 39 Issue 4, p503
Academic Journal
Aim: The aim of this study was to compare the antioxidative status in patients with colorectal cancer and healthy controls, based on measurements made using a novel method. Materials and Methods: The study was conducted between 2005 and 2007, and included 30 patients with colorectal cancer and 30 healthy controls. To determine the antioxidative status of the patients and healthy controls, serum total antioxidant capacity was measured using a novel automated method. Blood samples were taken from the healthy controls and the patients. Results: Total serum antioxidant capacity was significantly lower in colorectal cancer patients than in healthy persons (P < 0.023). Conclusions: Patients with colorectal cancer are exposed to oxidative stress, which may have a role in the pathogenesis of the disease. The novel automated method used in this study was developed in our laboratory, and is feasible and fully automated; therefore, it may be useful for evaluating oxidative-antioxidative balance in patients with colorectal cancer.


Related Articles

  • Sulindac, 3,3'-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis. Femia, Angelo Pietro; Soares, Paulo Victoria; Luceri, Cristina; Lodovici, Maura; Giannini, Augusto; Caderni, Giovanna // BMC Cancer;9/3/2015, Vol. 15 Issue 1, p1 

    Background: Recently, we showed that Sulindac (SU; 320 ppm) reduces precancerous lesions in the colon of Pirc rats, mutated in the Apc gene. Surprisingly, previous data in Apc-mutated mice showed that SU, with reported efficacy in Familial Adenomatous Polyposis (FAP), increases colon...

  • Four Jointed Box 1 Promotes Angiogenesis and Is Associated with Poor Patient Survival in Colorectal Carcinoma. Al-Greene, Nicole T.; Means, Anna L.; Lu, Pengcheng; Jiang, Aixiang; Schmidt, Carl R.; Chakravarthy, A. Bapsi; Merchant, Nipun B.; Washington, M. Kay; Zhang, Bing; Shyr, Yu; Deane, Natasha G.; Beauchamp, R. Daniel // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Angiogenesis, the recruitment and re-configuration of pre-existing vasculature, is essential for tumor growth and metastasis. Increased tumor vascularization often correlates with poor patient outcomes in a broad spectrum of carcinomas. We identified four jointed box 1 (FJX1) as a candidate...

  • Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects. Komura, Toshihiro; Miura, Koh; Shirasaka, Tetsuhiko; Ohnuma, Shinobu; Shimada, Miki; Kajiwara, Taiki; Fujishima, Fumiyoshi; Philchenkov, Alex; Nakagawa, Kei; Kudoh, Katsuyoshi; Haneda, Sho; Toshima, Masahide; Kohyama, Atsushi; Musha, Hiroaki; Naitoh, Takeshi; Shibata, Chikashi; Unno, Michiaki // International Journal of Clinical Oncology;Feb2015, Vol. 20 Issue 1, p117 

    Background: A clinical trial of S-1 with leucovorin (S-1/LV) in metastatic colorectal cancer (CRC) patients demonstrated promising efficacy; however, the gastrointestinal toxicities were so severe that it has not been applied in the clinical setting. On the other hand, alternate-day...

  • Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status. Lee, Jeeyun; Jain, Anjali; Kim, Phillip; Lee, Tani; Kuller, Anne; Princen, Fred; In-Gu; Kim, Suk Hyeong; Park, Joon Oh; Park, Young Suk; Singh, Sharat; Kim, Hee Cheol // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Background: Oncogenic mutational analysis provides predictive guidance for therapeutics such as anti-EGFR antibodies, but it is successful only for a subset of colorectal cancer (CRC) patients. Method: A comprehensive molecular profiling of 120 CRC patients, including 116 primary, 15 liver...

  • FOLFIRI plus panitumumab effective in metastatic colorectal cancer.  // Hem/Onc Today;2/10/2014, Vol. 15 Issue 3, p15 

    The article highlights the results of a study indicating that a treatment regimen consisting of FOLFIRI chemotherapy plus the prescription drug panitumumab could significantly enhance the progression-free survival (PFS) rates of metastatic colorectal cancer patients with KRAS wild-type tumors.

  • Cinnamaldehyde/ chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer. CHEN YU; SHEN-LIN LIU; MING-HAO QI; XI ZOU // Molecular Medicine Reports;2014, Vol. 9 Issue 2, p669 

    Cinnamaldehyde is an active monomer isolated from the stem bark of Cinnamomum cassia, a traditional oriental medicinal herb, which is known to possess marked antitumor effects in vitro and in vivo. The aim of the present study was to examine the potential advantages of using cinnamaldehyde in...

  • Screening and early diagnosis of colorectal cancer in China: a 12 year retrospect (1994–2006). Li, Shirong; Wang, Jiheng; Lu, Yuanyuan; Fan, Daiming // Journal of Cancer Research & Clinical Oncology;Oct2007, Vol. 133 Issue 10, p679 

    Colorectal cancer is one of the most prevalent malignancies in the world. Chinese researchers and clinical doctors had been working hard in the last 12 years, exploring efficient and convenient methods for screening and early diagnosis. The 12 years research works indicated that SFOBT plus...

  • Endoscopic follow-up after surgery for colorectal cancer. Loffeld, R. // International Journal of Colorectal Disease;Nov2015, Vol. 30 Issue 11, p1581 

    Objective: Follow-up surgery for colorectal cancer is recommended. The yield of endoscopy is unknown and was therefore studied. Methods: Patients with colorectal cancer in the years 2003, 2004 and 2005 were included. Evaluation was done in July 2014. Results: Cancer was diagnosed in 267...

  • Colorectal Cancer in Younger Patients. Bounedjar, Adda // Pan Arab Journal of Oncology;Jun2016, Vol. 9 Issue 2, p15 

    Background: The incidence of colorectal cancer in young patients is increasing. It remains unclear if the disease has unique features in this age group. Previous studies have suggested a poor outcome for patients presenting with colorectal cancer under the age of 40 years. Methods: This study...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics